Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Fadraciclib by Cyclacel Pharmaceuticals for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...
Fadraciclib by Cyclacel Pharmaceuticals for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...
Fadraciclib by Cyclacel Pharmaceuticals for Myelodysplastic Syndrome: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...
Fadraciclib by Cyclacel Pharmaceuticals for Ovarian Cancer: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
Fadraciclib by Cyclacel Pharmaceuticals for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According...
Fadraciclib by Cyclacel Pharmaceuticals for Cervical Cancer: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...
Fadraciclib by Cyclacel Pharmaceuticals for Endometrial Cancer: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...
Fadraciclib by Cyclacel Pharmaceuticals for Hepatocellular Carcinoma: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase...
Fadraciclib by Cyclacel Pharmaceuticals for Pancreatic Cancer: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...
Fadraciclib by Cyclacel Pharmaceuticals for Metastatic Biliary Tract Cancer: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Metastatic Biliary Tract Cancer. According to...
Fadraciclib by Cyclacel Pharmaceuticals for Uterine Cancer: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Uterine Cancer. According to GlobalData, Phase...
Fadraciclib by Cyclacel Pharmaceuticals for Unspecified B-Cell Lymphomas: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Unspecified B-Cell Lymphomas. According to GlobalData,...
Fadraciclib by Cyclacel Pharmaceuticals for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According to...